High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
2022 · JTO Clinical and Research Reports · 38 citations
https://doi.org/10.1016/j.jtocrr.2022.100328
K
Khvaramze Shaverdashvili
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
20
Papers
361
Citations
9
h-index
9
i10-index
Khvaramze Shaverdashvili is an academic researcher from University of Pittsburgh Medical Center. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Lung Cancer Diagnosis and Treatment & Peptidase Inhibition and Analysis. The author has an h-index of 9, co-authored 17 publications.
ORCID: 0009-0004-4328-2033Papers by this author
worksA phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
2023 · EClinicalMedicine · 7 citations
https://doi.org/10.1016/j.eclinm.2023.102317
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
2024 · JTO Clinical and Research Reports · 3 citations
https://doi.org/10.1016/j.jtocrr.2024.100669
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis
2024 · JTO Clinical and Research Reports · 1 citations
https://doi.org/10.1016/j.jtocrr.2024.100765
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat